How should I interpret peak expiratory flow (PEF) and spirometry (FEV₁, FEV₁/FVC) to assess asthma control in a patient on inhaled therapy?

Interpreting Peak Flow and Spirometry for Asthma Control

To assess asthma control on inhalers, prioritize pre-bronchodilator FEV₁ (% predicted) as your primary objective measure, aiming for ≥80% predicted, while recognizing that peak flow is inferior to spirometry for clinic assessment but useful for home monitoring of within-patient trends over time. 1

Spirometry Interpretation: The Gold Standard

Pre-Bronchodilator FEV₁

• Target: ≥80% predicted indicates better control and lower exacerbation risk
• Low FEV₁ (<80% predicted) is a strong, independent predictor of future asthma exacerbations 1
• Pre-bronchodilator FEV₁ provides complementary information that symptoms alone cannot capture 1

Critical Caveat About "Normal" Spirometry

Baseline FEV₁ is often within normal range in mild or well-controlled asthma, so normal spirometry does NOT rule out poor control 1. You must integrate spirometry with symptoms and other measures—they correlate only weakly 1.

FEV₁/FVC Ratio

• FEV₁/FVC <0.70 indicates airway obstruction and predicts increased oral steroid and rescue inhaler use 2
• This ratio helps confirm obstructive physiology characteristic of asthma

Bronchodilator Reversibility

• Improvement of ≥12% AND ≥200 mL in FEV₁ post-bronchodilator is significant 1
• Bronchodilator reversibility is an independent predictor of death from asthma 1
• Post-bronchodilator FEV₁ is recommended for long-term monitoring as it's less affected by smooth muscle tone variability 1

Minimal Important Difference

• A change of approximately 10% in FEV₁ represents a clinically meaningful difference based on patient perception 1

Peak Expiratory Flow: Know Its Limitations

When PEF Is Useful

• Best for ambulatory home monitoring with within-patient comparisons over time 1
• Use the same device consistently for serial measurements 1
• Target: lowest PEF ≥80% of patient's personal best over preceding 4 weeks 3

Why PEF Is Inferior to Spirometry in Clinic

PEF is inferior to FEV₁ as a clinic-measured parameter because it: 1

• Offers no advantage in reproducibility
• Lacks accurate reference values for many populations
• May underestimate airway obstruction in patients with airway remodeling
• Shows less accurate correlation with FEV₁ changes during bronchoconstriction 4

The Dangerous Pitfall

In 30% of patients with controlled symptoms, peak flow was NOT controlled 3. Similarly, 28% of patients with controlled symptoms AND normal FEV₁/FVC had uncontrolled peak flow 3. This means relying on symptoms or PEF alone risks undertreatment.

Practical Algorithm for Assessment

Step 1: Measure Pre-Bronchodilator Spirometry

• Obtain FEV₁ (% predicted) and FEV₁/FVC ratio
• If FEV₁ <80% predicted or FEV₁/FVC <0.70: Higher risk of exacerbations; consider treatment intensification 1, 2

Step 2: Assess Bronchodilator Response

• Administer short-acting bronchodilator
• Repeat spirometry after 10-15 minutes 1
• If improvement ≥12% AND ≥200 mL: Confirms reversible obstruction; may indicate suboptimal controller therapy 1

Step 3: Integrate with Symptoms

• Do NOT rely on symptoms alone—correlation with FEV₁ is weak 1
• Patients may report symptom improvement (e.g., on LABA) without any change in pre-bronchodilator FEV₁ 1
• Conversely, spirometry may be normal despite poor symptom control

Step 4: Consider Home Peak Flow Monitoring

• Reserve for patients needing closer monitoring or those with poor perception of symptoms
• Variability >20% suggests poor control 5
• Remember: PEF changes are less accurate than FEV₁ changes for detecting obstruction 4

Additional Considerations

FEF₂₅₋₇₅ (Mid-Expiratory Flow)

• FEF₂₅₋₇₅ <60% predicted correlates with increased oral steroid and rescue inhaler use 2
• May reflect small airway dysfunction
• Less standardized than FEV₁ but provides complementary information

Quality Control Issues

• Follow 2005 ATS/ERS spirometry performance guidelines 1
• Ensure proper technique—poor technique is a common reason for "uncontrolled" asthma 6
• Home spirometry requires accompanying diary for context (equipment issues, confounding events) 7

Timing of Measurements

• FEV₁ responds to fast-acting bronchodilators within 10 minutes (lasting ≥2 hours) 1
• ICS therapy improves FEV₁ within days, with effects lasting days to weeks after discontinuation 1

The Bottom Line on Control Assessment

Well-controlled asthma requires BOTH symptom control AND objective lung function measures. 6 The GOAL study showed that even with aggressive treatment, only about one-third of patients achieved total control, and morning PEF >80% predicted was part of the control definition 6.

Do not assume control based on symptoms alone—measure spirometry regularly, use pre-bronchodilator FEV₁ as your primary objective marker, and reserve peak flow for home monitoring trends rather than clinic-based decision-making.